A Metabolomic Approach to the Identification of Cancer Biomarkers

Slides:

Advertisements

Similar presentations

Introduction The incidence of prostate cancer in Asians is lower compared to the Westerners in men with PSA

Advertisements

Methods: Metabolomics Workflow Introduction Figure 1a: 1 H NMR spectrum of blood serum sample from a breast cancer patient. Results The emerging area of.

Nicola Barnstaple Programme Manager. Key challenges in Scotland Increasing cancer incidence – predicted 35,000 cases per year in 2020 Ageing population.

Bioinformatic Treatment of Human Metabolome Profile for Diagnostics Dr. Petr Lokhov & Dr. Alexander Archakov Institute of Biomedical Chemistry, RAMS.

Cross-border biomarker research of ovarian cancerCrossBiomark (HUSRB/1203/214/091) The project is co-financed by the European Union

University of Turku Department of Biochemistry Jukka-Pekka Suomela Biomarkers.

Microarrays: Tools for Proteomics

High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.

Technische Universität München Cancer biomarker discovery by chemical and quantitative proteomics Sebastian Berger, B. Sc., Center of Life and.

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

Prostate Cancer One of the commonest causes of death in the Western World USA 2005 – 232,090 new cases – 30,350 deaths Lifetime risk of disease 16.6% Lifetime.

Otis W. Brawley, M.D. Chief Medical and Scientific Officer Executive Vice President American Cancer Society Professor of Hematology, Medical Oncology,

Metabolic Signatures in Apoptotic Human Cancer Cell Lines Anna Halama 1, Gabriele Möller 1, and Jerzy Adamski 1,2 Vincent Torrecampo and Tammy Tran.

Is the rate of biological ageing, as measured by age at diagnosis of cancer, socio-economically patterned? Dr. Jean Adams School of Population and Health.

Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.

County-Level Estimates of Diagnosed Diabetes Incidence Among Adults Aged ≥ 20 Years Trends 2004 – 2009.

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 13 – BIOMARKERS Summary and final notes.

Exploring Metabolomic data with recursive partitioning Metabolomic Workshop NISS July 14-15, 2005.

Metabolomics 5/2/2014. ‘Omics Family Tree W. M. Claudino, et al., Journal of Clinical Oncology, 2007, 25(19), pp /2/2014.

What do we need to know about active ingredients? Workshop #1.

Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Cancer Biology.

“The African American Prostate Cancer Crisis in Numbers”

CCE project update Metabolomics Raftery Group. Original Study 20 cancer, 28 normals and 14 with polyps NMR and GC-MS study.

PCa Screening New Areas of Research Francesco Montorsi Milan.

Cancer Characteristics Yemi Oso Scott Asplund Anthony Pico Josh Strauss.

Metabolomics and analytical chemistry: GC & GCMS Simone Bossi Analytical Chemistry Lab – Plant Physiology – Plant Biology.

DEBIRI TACE Patterns and Predictors of Response

Reducing Cancer Disparities in Maryland: from Observations to Solutions Jean G. Ford, M.D. Director, Community-based Research Sidney Kimmel Comprehensive.

Understanding Cancer and Related Topics

 DR A. T, ATANDA BAYERO UNIVERSITY/AMINU KANO TEACHING HOSPITAL, KANO.

Gender & Non-Gender Specific Cancer. Quick Facts On average, 386 Canadian men will be diagnosed with prostate cancer every week. On average, 407 Canadian.

The Burden of Cancer in Connecticut Lou Gonsalves Connecticut Tumor Registry

The Cancer Burden in Iowa: Data Overview. Treatment BirthDeathCancer Diagnosis Genes Environment Etiology & Prevention Early Detection Quantity & Quality.

United States Cancer Statistics 2002 Incidence and Mortality

South West Public Health Observatory South West Regional Public Health Group Opportunities for future analysis by SWPHO Sean McPhail South West Public.

Prostatectomy operations in England South West Public Health Observatory Trends in the use of radical prostatectomy in England Sean McPhail.

Variation in place of death from cancer: studies in South East England Elizabeth Davies, Peter Madden, Victoria Coupland, Karen Linklater, Henrik Møller.

MP60-03 PROSTATE CANCER IN THE ELDERLY

89 PSA recurrences over median follow-up of 11.3 years

Volume 179, Issue 2, Pages (February 2008)

miR p Is a Novel Prognostic Biomarker of Prostate Cancer

Volume 195, Issue 4, Pages e13-e14 (April 2016)

SIGNIFICANCE OF THE STUDY

International Neurourology Journal 2014;18:

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Integrated Metabolomics Research Group, Korea Basic Science Institute

Knowledge l Action l Impact

Volume 71, Issue 2, Pages (February 2017)

Young Belgium Magnetic Resonance Scientist 2014

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Prostate Cancer Epidemic in Sight?

Willie Underwood, III, MD, MS,MPH

The Potential of MicroRNAs as Prostate Cancer Biomarkers

Towards Early and More Specific Diagnosis of Prostate Cancer

Volume 184, Issue 4, Pages (October 2010)

Volume 185, Issue 2, Pages (February 2011)

Prostate Cancer Epidemic in Sight?

Global Burden of Urologic Cancers, 1990–2013

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Figure 1 A schematic representation of the role

Volume 25, Issue 3, Pages (March 2017)

Volume 53, Issue 1, Pages (January 2008)

Department of Biochemistry and Molecular Biology

European Urology Oncology

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Does PSA Testing Influence the Natural History of Prostate Cancer?

Cases of and deaths from prostate cancer, with associated age-standardized incidence and mortality (per men), among Canadian men aged 45 years.

Presentation transcript:

A Metabolomic Approach to the Identification of Cancer Biomarkers Clive Baveghems Bioanalytical Chemistry Spring 2011

Outline What is Metabolomics? Metabolomic screening for the identification of cancer biomarkers Metabolomic screening for the identification of prostate cancer biomarkers

Introduction to Metabolomics Sawyer, J. Surg. Oncol. 2010; 21831: 2

Yearly increase in Metabolomics publications Note: 2010 total ~ 750 Ong, Trends in Analytical Chemistry 2010; 29(3):270

Factors influencing the Metabolome Sawyer, J. Surg. Oncol. 2010; 21831: 2

Outline What is Metabolomics?√ Metabolomic screening for the identification of cancer biomarkers Metabolomic screening for the identification of prostate cancer biomarkers

Biomarker Identification Sawyer, J. Surg. Oncol. 2010; 21831: 4

Cancer biomarkers identified so far Sawyer, J. Surg. Oncol. 2010; 21831: 5

Key Metabolites implicated so far Sawyer, J. Surg. Oncol. 2010; 21831: 6

Outline What is Metabolomics?√ Metabolomic screening for the identification of cancer biomarkers√ Metabolomic screening for the identification of prostate cancer biomarkers

Prostate Cancer From 2003-2007 median age for diagnosis was 67 The age-adjusted incidence rate was 156.9/100, 000 men per year The median age at death was 80 The age-adjusted death rate was 24.7/100, 000 men per year http://seer.cancer.gov/statfacts/html/prost.html

Results from LC and GC-MS Chinnaiyan, Nature 2009; 457(12): 911

Sarcosine identified as a biomarker for prostate cancer Chinnaiyan, Nature 2009; 457(12): 913

Is sarcosine a biomarker for prostate cancer? GC-MS data Jung, Journal of Urology 2011; 185: 708

Summary Metabolomics has emerged as a fast and efficient method for the identification of a small set of candidate biomarkers from a large eclectic data set LC/MS, GC/MS, and NMR are important metabolomic technologies Future studies will further explain sarcosine’s role in Prostate Cancer

References Metabolomics and Surgical Oncology: Potential Role for Small Molecule Biomarkers Sawyer, J. Surg. Oncol. 2010; 21831: 1-9 Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Chinnaiyan, Nature 2009; 457(12): 910-915 Sarcosine in Prostate Cancer Tissue is Not a Differential Metabolite for Prostate Cancer Progressiveness and Biochemical Progression Jung, Journal of Urology 2011; 185: 706-711 Experiment-originated variations, and multi-peak and muti-origination phenomena in derivatization-based GC-MS metabolomics Ong, Trends in Analytical Chemistry 2010; 29(3):269-280